Novel screening approach for developing new stable biotherapeutic formulations

开发新的稳定生物治疗制剂的新筛选方法

• 批准号: 101721
• 金额: $ 79.49万
• 依托单位: ARECOR LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101721
• 关键词: Novel; screening; approach; developing; new

A growing number of drugs that are being developed to combat infection and disease are protein based "biotherapeutics". The supply of these vital biotherapeutics is limited only to areas where there is a sufficient cold-chain i.e. fridges/freezers. Arecor is a biotherapeutic formulation company that has developed technology to stabilise liquid formulations to improve their shelf life. In collaboration with Manchester University's Centre of Excellence in Biopharmaceuticals, Arecor will use the TSB formulated product grant to fund the development of the next generation liquid biotherapeutic formulations that are room temperature stable starting with a new room temperature stable formulation of fast acting insulin. These new biotherapeutic formulations can be shipped to any part of the world without the need for cold-chain storage. Unilever, Lilly and PrismTC will all assist in the development of this new technology that will improve healthcare provision to the third world and reduce the environmental burden of cold-chain provision.

正在开发的越来越多的用于对抗感染和疾病的药物是基于蛋白质的“生物治疗剂”。这些重要的生物治疗药物的供应仅限于有足够冷链即冰箱/冰柜的地区。Arecor是一家生物制剂公司，开发了稳定液体制剂以延长其保质期的技术。与曼彻斯特大学生物制药卓越中心合作，Arecor将使用TSB配制产品赠款资助下一代室温稳定的液体Biofilm制剂的开发，从一种新的室温稳定的速效胰岛素制剂开始。这些新的生物制剂可以被运送到世界任何地方，而不需要冷链储存。联合利华、礼来和PrismTC都将协助开发这项新技术，以改善对第三世界的医疗保健服务，并减少冷链供应的环境负担。